Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 07, 2019 16:05 ET | Source: Aduro Biotech, Inc.

Aduro Biotech Provides Business Update and Reports Third Quarter 2019 Financial Results

BERKELEY, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of...
October 02, 2019 16:05 ET | Source: Aduro Biotech, Inc.

Aduro Biotech Announces Two Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer 34th Annual Meeting (SITC 2019)

BERKELEY, Calif., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of...
September 30, 2019 16:05 ET | Source: Aduro Biotech, Inc.

Aduro Biotech to Present at the 2019 Cantor Global Healthcare Conference

BERKELEY, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that Andrea van Elsas, chief scientific officer of Aduro, is scheduled to present at the 2019...
September 04, 2019 08:30 ET | Source: Aduro Biotech, Inc.

Aduro Biotech Announces First Patient Dosed in Phase 2 Study of ADU-S100 (MIW815) in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

BERKELEY, Calif., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of...
September 03, 2019 16:05 ET | Source: Aduro Biotech, Inc.

Aduro Biotech to Present at the H.C. Wainwright 21st Annual Global Investment Conference

BERKELEY, Calif., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, is scheduled...
August 01, 2019 16:05 ET | Source: Aduro Biotech, Inc.

Aduro Biotech Provides Business Update and Reports Second Quarter 2019 Financial Results

BERKELEY, Calif., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of...
June 02, 2019 11:45 ET | Source: Aduro Biotech, Inc.

Aduro Biotech and Novartis Present Results from Ongoing Phase 1b Study of STING Agonist ADU-S100 (MIW815) in Combination with Anti-PD-1 Monoclonal Antibody Spartalizumab (PDR001) in Patients with Advanced Solid Tumors or Lymphomas

ADU-S100 (MIW815) + spartalizumab combination data demonstrated antitumor activity in anti-PD-1-naïve triple-negative breast cancer (TNBC) and previously immunotherapy-treated melanoma As of the April...
May 15, 2019 17:06 ET | Source: Aduro Biotech, Inc.

Aduro Biotech to Host Investor Event Featuring ADU-S100 (MIW815) Clinical Data Presented at the 2019 American Society of Clinical Oncology Annual Meeting

BERKELEY, Calif., May 15, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of...
May 15, 2019 17:05 ET | Source: Aduro Biotech, Inc.

Aduro Biotech Announces Clinical Program Update for Anti-APRIL Antibody BION-1301

First healthy volunteer cohort cleared in Phase 1 first-in-human study of BION-1301 for the treatment of IgA nephropathy (IgAN); initial data in healthy volunteers expected in H1 2020 and IgAN...
May 07, 2019 16:05 ET | Source: Aduro Biotech, Inc.

Aduro Biotech Reports First Quarter 2019 Financial Results

BERKELEY, Calif., May 07, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of...